At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
perampaneldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 Years of Age With Epilepsy
In Brief
A Phase 2 clinical trial evaluating perampanel for Epilepsy. Completed, enrolled 26 participants across 18 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants from 1 month to less than 4 years of age with epilepsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesLatvia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartFeb 2017
Primary CompletionAug 2022
Study CompletionApr 2023
TodayJul 2026
First PostedSep 26, 2016
Enrollment StartFeb 20, 2017
Primary CompletionAug 23, 2022
Study CompletionApr 25, 2023
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 9.8 years ago
Interventions
perampaneldrug
oral suspension.